Intravenous Valproate versus Subcutaneous Sumatriptan in Acute Migraine Attack
,
Abstract
Migraine is a common and incapacitating neurologic disorder manifesting with episodic moderate to a severe headache and other symptoms such as photophobia, phonophobia, nausea, and vomiting. Triptans and ergot compounds have been used as treatment options for an acute migraine headache for many years. Triptans are considered the first line of treatment in patients with moderate to a severe migraine. Although the triptans are commonly used at any time during a migraine attack; they are more efficacious when used in the early stages of a migraine. Intravenous valproic acid has been shown to be well tolerated, safe, and with rapid onset of action in patients with acute moderate to severe and even refractory migraine. Sodium valproate is a Food and Drug Administration (FDA)–approved drug for prophylaxis of a migraine with and without aura. In this study, the main goal was to compare the effectiveness of sumatriptan versus valproate in an acute migraine. A randomized clinical trial including 37 patients with an acute migraine was considered to compare the effectiveness of sumatriptan versus valproate. The patients were divided into two groups. In first group, 6 mg subcutaneous of sumatriptan and in the second group 15 mg/Kg of valproate was administered. The outcomes including pain and drug adverse effects were compared across the groups. A total of 37 patients (7 male and 30 female) were evaluated in two groups. The difference between two groups regarding sex and age was not significant (P>0.05). The mean pain scores reduced from 8.3 to 4.7 and from 8.3 to 2.2 after one hour of treatment in sumatriptan and valproate groups, respectively. Response to treatment in valproate group was faster and more effective than sumatriptan group (P < 0.05).The results indicated that valproate was more effective and with the faster response in patients with an acute migraine in comparison with sumatriptan without any recurrence and remarkable side effects.
Ghorbani A, Chitsaz A. Primary Headaches: Classification and Diagnosis. J Isfahan Med School 2008;27(99):551-61.
Ducros A. Mechanisms and genetics of migraine. CNS drugs. 2005;20(Spec no):1-11.
Andrasik F, Schwartz MS. Behavioral assessment and treatment of pediatric headache. Behav Modif 2006;30(1):93-113.
Tepper SJ, Spears RC. Acute treatment of migraine. Neurol Clin 2009;27(2):417-27.
Goadsby PJ, Lipton RB, Ferrari MD. Migraine--current understanding and treatment. New Engl J Med 2002;346(4):257-70.
Stovner L, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 2007;27(3):193-210.
Bigal ME, Lipton RB. The epidemiology, burden, and comorbidities of migraine. Neurol Clin 2009;27(2):321-34.
Sadeghniiat K, Rajabzadeh A, Ghajarzadeh M, et al. Sleep Quality and Depression among Patients with Migraine. Acta Med Iran 2013;51(11):784-8.
Breivik H, Collett B, Ventafridda V, et al. Survey of= chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006;10(4):287-333.
Fichtel Å. Recurrent headache among Swedish adolescents: Psychosocial factors, coping and effects of relaxation treatment [Dissertation]. Uppsala Univ., 2003.
Boes CJ, Capobianco DJ, Ctrer FM, et al. Headache and Other Craniofacial Pain. In: Bradley WG, Daroff RB, Fenichel GM, et al, editors. Neurology in clinical practice. 5th ed. Heinemann: Butterworth; 2008. p. 2026-42.
Mathew NT, Kailasam J, Meadors L, et al. Intravenous valproate sodium (depacon) aborts migraine rapidly: a preliminary report. Headache 2000;40(9):720-3.
Derry CJ, Derry S, Moore RA. Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 2012;2:CD009665.
Shahien R, Saleh S, Bowirrat A. Intravenous sodium valproate aborts migraine headaches rapidly. Acta Neurol Scand 2011;123(4):257-65.
Derry CJ, Derry S, Moore RA. Sumatriptan (oral route of
Edwards KR, Norton J, Behnke M. Comparison of Intravenous Valproate Versus Intramuscular Dihydroergotamine and Metoclopramide for Acute Treatment of Migraine Headache. Headache 2001;41(10):976-80.
Bakhshayesh B, Seyed Saadat SM, Rezania K, et al. A randomized open-label study of sodium valproate vs sumatriptan and metoclopramide for prolonged migraine headache. Am J Emerg Med. 2013 Mar;31(3):540-4.
Yurekli VA, Akhan G, Kutluhan S, et al. The effect of sodium valproate on chronic daily headache and its subgroups. J Headache Pain 2008;9(1):37-41.
| Files | ||
| Issue | Vol 53, No 10 (2015) | |
| Section | Original Article(s) | |
| Keywords | ||
| Migraine Sumatriptan Sodium valproate | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
